Local generic pharmaceuticals giant Mylan upped the stakes in its courtship dance for fellow drugmaker Perrigo on Wednesday, preening its feathers and boosting its offer only to be spurned for a third time.

The revised bid for Perrigo came just two days after Mylan itself harshly rejected a takeover offer from Israel’s Teva Pharmaceutical Industries in a three-way whirlwind of potential deal-making in recent weeks that has seen offers and rejections fly at an unusually swift pace.

Teva late Wednesday reached out to Mylan through a letter asking that the company stop the type of disparaging remarks made earlier in the week and to meet formally to hash out a merger agreement.

Mylan’s latest offer for Perrigo was for $75 in cash and 2.3 Mylan shares for each share of Perrigo, up from $60 in cash and 2.2 shares. The new offer values Perrigo at $242.23 per share based on Mylan’s closing price Tuesday, up from $227.33 in its previous offer, for a total value of some $35 billion.

Advertise with us

“With this enhanced offer, I look forward to meeting with [Perrigo chairman and CEO] Joe Papa and his team to finalize the implementation of this truly compelling combination,” Mylan chairman Robert Coury said in a statement issued Wednesday morning.

But Perrigo took less than two hours to rebuff the new bid, calling it insufficient and inferior to Mylan’s initial offer. The maker of generic and over-the-counter medicines reiterated its earlier contention that Mylan is trying to make the purchase using shares that have been artificially inflated by Teva’s advances.

“Shareholders are strongly advised to take no action in relation to [Mylan’s] offer,” Perrigo said in its statement.

S&P Capital IQ analyst Jeffrey Loo said Mylan will have to increase the cash portion of the bid and lower the stock portion if it hopes to win over its target.

“Perrigo does have a decent argument by stating that Mylan shares technically have been inflated by Teva’s rumored bid in March and Teva’s actual bid in April,” Mr. Loo said. “It’s hard for them to wrap their heads around the true value.”

Advertise with us

Mylan’s pursuit of Perrigo — known for its store-brand drugs that compete with brand names such as Sudafed, Pepcid and NyQuil — has been widely viewed as a defensive move aimed at fending off Teva or another large suitor.

Canaccord Genuity analyst Corey Davis has said he believes Mylan — which reincorporated in the Netherlands for tax purposes but maintains its base of operations in Cecil — won’t succeed with Perrigo unless Teva withdraws its offer. That would allow Mylan’s share price to settle into a more normal range.

Teva, the world’s biggest generic drug producer, has vowed to press ahead with its $82 cash-and-stock offer for Mylan, valued at more than $40 billion. The company is said to be lobbying Mylan’s biggest shareholders directly to win their support.

Mr. Loo said Teva likely is trying to gauge what Mylan shareholders would be willing to take.

Teva issued a statement early Wednesday reiterating its resolve, calling a Teva-Mylan combination “more attractive for Mylan stockholders than any other alternative.”

Advertise with us

In his rejection letter to Teva’s CEO on Monday, Mr. Coury derided that company as “troubled” with a “problematic culture and leadership.”

And he said the starting point for any merger discussions would have to be “significantly in excess of $100 per share.”

Mr. Loo thought that price tag sounded high. “I don’t think it will take something of that magnitude to get Mylan shareholders interested,” he said.

Late on Wednesday, Teva released a five-page letter that its CEO, Erez Vigodman, had sent to Mr. Coury asking him to stop the “mudslinging” leveled in Monday’s rejection letter and to “engage constructively” to work out a deal.

Mylan’s letter painted a “fundamentally distorted picture” of Teva and its rich heritage, Mr. Vigodman wrote.

Advertise with us

“Summarily rejecting our offer, which provides Mylan stockholders with such a significant premium, is inconsistent with the responsibilities and obligations of your board of directors to Mylan’s stakeholders,” he said.

He said the swipes at Teva’s board and leadership team were unfounded, adding that the company was “committed to cost control and restraint at all levels.”

“This includes our approach to executive pay and perquisites, which favors restraint and a pay-for-performance philosophy,” Mr. Vigodman said.

Meanwhile, Perrigo said Mylan’s latest bid was actually worth more like $202 a share, instead of $242, if it were based on Mylan’s “unaffected” share price of $55.31 on March 10. That was the last day of trading prior to widespread public speculation that Teva was considering an offer for Mylan.

Price wasn’t the only reason Perrigo’s board rejected Mylan, Mr. Papa said in a conference call last week. “The board believes that we have a strong business plan as an independent company,” he said.

Advertise with us

Observers expected the drama to continue, with speculation heating up Wednesday that rival bidders would emerge for Perrigo.

Sanford Bernstein analyst Ronny Gal said if Mylan were to raise its bid much more, it might meet Perrigo’s requirements, “but [Mylan] would be paying too much.”

He said Mylan executives would be hitting the road next week to talk with Perrigo investors.

Mylan’s shares rose $1.79, or 2.46 percent, to close Wednesday at $74.50. Perrigo lost $1.64, or 0.88 percent, to close at $184.75, while Teva gained 85 cents, or 1.39 percent, to $62.15.

Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.